Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE-013 study
Authors
John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Canada.
Philippe Armand, Dana-Farber Cancer Institute, Boston, MA, USA.
Mehdi Hamadani, Medical College of Wisconsin, Milwaukee, WI, USA.
Justin Kline, Department of Medicine, University of Chicago, Chicago, IL, USA.
Craig H. Moskowitz, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
David Avigan, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vincent Ribrag, Gustave Roussy, Villejuif, France.
Alex F. Herrera, City of Hope, Duarte, CA, USA.
Franck Morschhauser, Department of Hematology, CHU Lille, Lille University, Lille, France.
Abraham Kanate, HonorHealth Cancer Transplant Institute, Scottsdale, AZ, USA.
Pier Luigi Zinzani, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Jacob Bitran, Advocate Aurora HealthFollow
Herve Ghesquieres, Lyon-Sud Hospital Center, Lyon, France.
Stephen J. Schuster, Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Mohammed Farooqui, Merck & Co., Inc., Rahway, NJ, USA.
Patricia Marinello, Merck & Co., Inc., Rahway, NJ, USA.
Nancy L. Bartlett, Siteman Cancer Center, Washington University, St. Louis, MO, USA.
Recommended Citation
Kuruvilla J, Armand P, Hamadani M, et al. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma. 2023;64(1):130-139. doi:10.1080/10428194.2022.2136956
Abstract
The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (auto-HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15-31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and 'other' NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20-61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.
Affiliations
Advocate Lutheran General Hospital